Federal Register / Vol. 72, No. 46 / Friday, March 9, 2007 / Notices 10771 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel, 

Development of Molecular 

Pharmacodynamic Assays for Targeted 

Therapies. 

Date: March 16, 2007. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: Marriott Bethesda North Hotel & 

Conference Center, 5701 Marinelli Road, 

Bethesda, MD 20852. 

Contact Person: C. Michael Kerwin, PhD, 

MPH, Scientific Review Administrator, 

Special Review and Logistics Branch, 

Division of Extramural Activities, National 

Cancer Institute, NIH, 6116 Executive Blvd., 

Rm. 8057, Bethesda, MD 20892–8329, 301–

496–7421, kerwinm@mail.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: March 5, 2007. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–1123 Filed 3–8–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meeting 

The National Cancer Advisory Board’s 

Breast Cancer Prevention Trial P–4 

Working Group will meet to discuss the 

P–4 trial which is designed to perform 

a 10-year study in risk-eligible, 

postmenopausal women to determine 

whether letrozole is more effective than 

raloxifene in reducing the incidence of 

invasive breast cancer in this otherwise 

healthy population. The meeting will be 

closed to the public. 

The thoughts and input from this 

meeting will be summarized in a report 

that will be presented to the National 

Cancer Advisory Board in open session 

at an upcoming meeting. 

Name of Work Group: National Cancer 

Advisory Board, Breast Cancer Prevention 

Trial P–4 Working Group. 

Closed: March 23, 2007, 8:30 a.m. to 4:30 

p.m. 

Agenda: The purpose of the work Group 

will be to ensure that funds are invested 

optimally to achieve outcomes that utilize 

the best of clinical and molecular sciences to 

answer key scientific questions, produce 

extremely valuable data sets for the 

community, and, in this instance, provide 

maximal benefit to breast cancer patients. 

Place: Hyatt Regency Bethesda, One Metro 

Center, Bethesda, MD 20814. 

Contact Person: Dr. Paulette S. Gray, 

Executive Secretary, National Cancer 

Advisory Board, National Cancer Institute, 

National Institutes of Health, 6116 Executive 

Boulevard, 8th Floor, Room 8001, Bethesda, 

MD 20892–8327, (301) 496–5147. 

SUPPLEMENTARY INFORMATION: 

Background 

Over the past several years the 

National Cancer Institute has performed 

a series of important prevention clinical 

trials to study the effect(s) of tamoxifen, 

raloxifene (Selective Estrogen Receptor 

Modulators—SERMS) and, 

subsequently, aromatase inhibitors such 

as letrozole on reducing the incidence of 

invasive breast cancer in defined 

populations of postmenopausal women. 

As follow-on to this series of breast 

cancer prevention trials, a new trial in 

the sequence, the P–4 trial, has been 

proposed and peer-reviewed. The P–4 

trial is designed to perform a 10-year 

study in risk-eligible, post menopausal 

women to determine wether letrozole is 

more effective than raloxifene in 

reducing the incidence of invasive 

breast cancer in this otherwise healthy 

population. The trial will accrue 12,800 

patients over 4 years. The primary 

endpoint for this trial will be the first 

occurrence of invasive breast cancer. 

Secondary endpoints will include DCSI; 

LCIA, ischemic heart disease; fracture of 

the wrist, hip, and spine; DVTs; PEs; 

TIAs and stroke; death; other invasive 

cancers; and quality of life. 

The P–4 trial is a significant financial 

commitment on the part of the National 

Cancer Institute and of the cancer 

research community. Additionally, the 

outcome of this trial will require more 

than 10 years of study. Given the 

magnitude of this investment, the rapid 

acceleration of progress is molecular 

genetics and molecular biology, and the 

disparate range of views on the trial, the 

National Cancer Advisory Board is 

convening a group of experts to provide 

feedback to the National Cancer 

Advisory Board. 

Any interested person may file 

written comments with the work group 

by forwarding the statement to the 

Contact Person listed in this notice. This 

statement should include the name, 

address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control; National Institutes of Health, 

HHS) 

Dated: March 5, 2007. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–1126 Filed 3–8–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Human Genome Research 

Institute; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Human 

Genome Research Institute Special Emphasis 

Panel, GEI Genotyping and Coordinating 

Centers. 

Date: March 30, 2007. 

Time: 8:30 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Embassy Suites at the Chevy Chase 

Pavilion, 4300 Military Road, NW., 

Washington, DC 20015. 

Contact Person: Rudy O. Pozzatti, PhD, 

Scientific Review Administrator, Office of 

Scientific Review, National Human Genome 

Research Institute, National Institutes of 

Health, Bethesda, MD 20892, 301–402–0838. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.172, Human Genome 

Research, National Institutes of Health, HHS) 


jlentini on PROD1PC65 with NOTICES
10772 Federal Register / Vol. 72, No. 46 / Friday, March 9, 2007 / Notices 

Dated: March 5, 2007. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–1112 Filed 3–8–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Environmental 

Health Sciences; Amended Notice of 

Meeting 

Notice is hereby given of a change in 

the meeting of the National Institute of 

Environmental Health Sciences Special 

Emphasis Panel, March 15, 2007, 7 p.m. 

to March 16, 2007, 6 p.m., The Radisson 

Governor’s Inn, I–40 at Davis Drive, Exit 

280, Research Triangle Park, NC 27709 

which was published in the Federal 

Register on February 13, 2007, fr13fe07–

60. 

The meeting will be held 8 a.m. to 5 

p.m. on both days. The meeting is 

closed to the public. 

Dated: March 1, 2001. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–1088 Filed 3–8–07; 8:45 am] 

BILLING CODE 4140–07–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Environmental 

Health Sciences, Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Environmental Health Sciences Special 

Emphasis Panel, Review of Pathway to 

Independence Application (Career 

Development). 

Date: March 21, 2007. 

Time: 2 p.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: NIEHS/National Institutes of Health, 

Building 4401, East Campus, 79 T.W. 

Alexander Drive, Research Triangle Park, NC 

27709 (Telephone Conference Call). 

Contact Person: Linda K Bass, PhD, 

Scientific Review Administrator, Scientific 

Review Branch, Division of Extramural 

Research & Training, Nat. Institute of 

Environmental Hlth. Sciences, P.O. Box 

12233, MD EC-30, Research Triangle Park, 

NC 27709, 919/541–1307. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: National Institute of 

Environmental Health Sciences Special 

Emphasis Panel, Review of Biological 

Response Indicators of Environmental Stress 

Centers (U54) and Biomarkers (U01). 

Date: March 29–31, 2007. 

Time: 1 p.m. to 1 p.m. 

Agenda: The review and evaluate grant 

applications. 

Place: Marriott, Charlotte, NC. 

Contact Person: Linda K Bass, PhD, 

Scientific Review Branch, Office of Program 

Operations, Division of Extramural Research 

and Training, Nat. Institute of Environmental 

Health Sciences, P. O. Box 12233, MD EC-30, 

Research Triangle Park, NC 27709, (919) 541–

1307. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.115, Biometry and Risk 

Estimation—Health Risks from 

Environmental Exposures; 93.142, NIEHS 

Hazardous Waste Worker Health and Safety 

Training; 93.143, NIEHS Superfund 

Hazardous Substances—Basic Research and 

Education; 93.894, Resources and Manpower 

Development in the Environmental Health 

Sciences; 93.113, Biological Response to 

Environmental Health Hazards; 93.114, 

Applied Toxicological Research and Testing, 

National Institutes of Health, HHS). 

Dated: March 1, 2007. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–1089 Filed 3–8–07; 8:45 am] 

BILLING CODE 4140–07–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Aging; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Aging Special Emphasis Panel, Drug Studies. 

Date: March 6, 2007. 

Time: 1 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute on Aging, 

Gateway Building, 7201 Wisconsin Avenue, 

Suite 2C212, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Louise L. Hsu, PhD, Health 

Scientist Administrator, Scientific Review 

Office, National Institute on Aging, Gateway 

Building, 7201 Wisconsin Avenue Suite 

2C212, Bethesda, MD 20892, (301) 496–7705, 

hsul@exmur.nia.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: National Institute on 

Aging Special Emphasis Panel, Modeling the 

Decision to Retire. 

Date: March 16, 2007. 

Time: 9 a.m. to 1 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda North Marriott, 5701 

Marinelli Road, Bethesda, MD 20852. 

Contact Person: Wilbur C. Hadden, PhD, 

Health Science Administrator, National 

Institute on Aging, Gateway Building, Room 

2C212, 7201 Wisconsin Avenue, Bethesda, 

MD 20892, haddenw@mail.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: National Institute on 

Aging Special Emphasis Panel, Elder 

Mistreatment 2007 RFA Meeting. 

Date: March 26–27, 2007. 

Time: 4 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute on Aging, 

Gateway Building, 7201 Wisconsin Avenue, 

2C212, Bethesda, MD 20892. 

Contact Person: Jon E. Rolf, PhD, Scientific 

Review Administrator, Scientific Review 

Office, National Institute on Aging, Bethesda, 

MD 20814, (301) 402–7703, rolfj@nia.nih.gov. 

Name of Committee: National Institute on 

Aging Special Emphasis Panel, Foundations 

of Economic Behavior. 

Date: March 26–27, 2007. 

Time: 4 p.m. to 3:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Residence Inn Marriott, 7335 

Wisconsin Ave, Bethesda, MD 20814. 

Contact Person: Wilbur C. Hadden, PhD, 

Health Science Administrator, National 

Institute on Aging, Gateway Building, Room 

2C212, 7201 Wisconsin Avenue, Bethesda, 

MD 20892, haddenw@mail.nih.gov. 


jlentini on PROD1PC65 with NOTICES